Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA
(mRNA) therapeutics and vaccines, today announced a new supply agreement with
Taiwan for 20 million doses of Moderna’s COVID-19 vaccine and its updated
variant booster vaccine candidate, if authorized, to begin delivery in 2022
and an additional 15 million doses in 2023. This new supply agreement is in
addition to the prior agreement for 5 million doses in 2021.

“We thank Taiwan for their support in securing this new agreement to supply in
2022 and 2023 our mRNA COVID-19 vaccine and our updated variant booster
candidate, if approved,” said Stéphane Bancel, Moderna’s Chief Executive
Officer. “We remain committed to making our vaccine available around the
world.”